Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study

Blood blood.2024025746.

https://doi.org/10.1182/blood.2024025746

Published: 2024

Includes: Supplemental data

Journal Articles

Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara‐Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Multiple Myeloma (MM) Eligible for High‐Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)

Peter M. Voorhees, MD, Cesar Rodriguez, MD, Brandi Reeves, MD, Nitya Nathwani, MD, Luciano J Costa, MD PhD, Yana Lutska, PharmD, Daniela Hoehn, MDPhD, Huiling Pei, PhD, Jon Ukropec, PhD, Ming Qi, MD PhD, Thomas Lin, MD PhD, Paul Richardson

Blood (2018) 132 (Supplement 1): 151.

https://doi.org/10.1182/blood-2018-151

Published: 2018

Journal Articles

Lyra: A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM)

Habte Yimer, MD, Jason Melear, MD, Edward Faber, DO, MS, William Bensinger, MD, John M Burke, Mohit Narang, MD, Don Stevens, MD, Sriya W. Gunawardena, MD, Yana Lutska, PharmD, Keqin Qi, PhD, Jon Ukropec, PhD, Ming Qi, MD PhD, Thomas Lin, MD PhD, Robert M Rifkin, MD

Blood (2018) 132 (Supplement 1): 152.

https://doi.org/10.1182/blood-2018-152

Published: 2018

Journal Articles

Interim Safety Analysis of a Phase 2 Randomized Study of Daratumumab (Dara), Lenalidomide (R), Bortezomib (V), and Dexamethasone (d; Dara-Rvd) Vs. Rvd in Patients (Pts) with Newly Diagnosed Multiple Myeloma (MM) Eligible for High‐Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)

Peter M. Voorhees, MD, Luciano J. Costa, MD PhD, Brandi Reeves, MD, Nitya Nathwani, Cesar Rodriguez, MD, Yana Lutska, Laura Hydutsky, Huiling Pei, Jon Ukropec, Ming Qi, Thomas Lin, Paul G Richardson, MD

Blood (2017) 130 (Supplement 1): 1879.

https://doi.org/10.1182/blood.V130.Suppl_1.1879.1879

Published: 2017

Journal Articles

Results of an Interim Safety Analysis of a Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Previously Untreated and Relapsed Patients (Pts) with Multiple Myeloma (MM)

Habte Yimer, MD, Jason Melear, MD, Edward Faber, William I. Bensinger, MD, John M Burke, MD, Sriya Gunawardena, MD, Murphy Sean, Hollee Parros, Yana Lutska, Mohamed Darif, PhD, Anil Londhe, PhD, Ming Qi, Jon Ukropec, Thomas Lin, Robert M. Rifkin, MD

Blood (2017) 130 (Supplement 1): 1839.

https://doi.org/10.1182/blood.V130.Suppl_1.1839.1839

Published: 2017

Journal Articles

Results of an Early Access Treatment Protocol (EAP) of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma

Ajai Chari, MD, Tomer M Mark, MD MSc, Amrita Krishnan, Keith Stockerl-Goldstein, Saad Z Usmani, MD FACP, Anil Londhe, Delores Etheredge, Hollee Parros, Sarah Fleming, Baolian Liu, Scott Freeman, Jon Ukropec, PhD, Thomas Lin, Sagar Lonial, MD FACP

Blood (2016) 128 (22): 2133.

https://doi.org/10.1182/blood.V128.22.2133.2133

Published: 2016

Journal Articles

Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma

Blood (2016) 128 (22): 2142.

https://doi.org/10.1182/blood.V128.22.2142.2142

Published: 2016

Journal Articles

Cyclophosphamide Remains An Important Component of Treatment in CLL Patients Receiving Pentostatin and Rituximab Based Chemoimmunotherapy

Neil E. Kay, Wenting Wu, John C. Byrd, MD, Brian Kabat, Diane F. Jelinek, PhD, Clive S. Zent, MD, Timothy Call, Thomas Lin, MD, PhD, Tait Shanafelt

Blood (2008) 112 (11): 43.

https://doi.org/10.1182/blood.V112.11.43.43

Published: 2008

Journal Articles

Natural Killer Cell Immune Reconstitution Predicts Outcomes for Patients with Chronic Lymphocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation

Don Benson, Leslie Andritsos, Mehdi Hamadani, Thomas Lin, Joseph Flynn, Jeffrey Jones, William Blum, MD, Patrick Elder, Gerard Lozanski, John Byrd, Steven Devine

Blood (2008) 112 (11): 3300.

https://doi.org/10.1182/blood.V112.11.3300.3300

Published: 2008

Journal Articles

17-DMAG Targets the NF-κB Family of Proteins to Induce Apoptosis in CLL: Clinical Implications of Hsp90 Inhibition

Amy J Wagner, Erin K Hertlein, PhD, Chelsey A Raymond, Derek A West, Joseph M Flynn, DO, MPH, Thomas Lin, MD, PhD, Amy J Johnson, PhD, John C Byrd, MD

Blood (2008) 112 (11): 381.

https://doi.org/10.1182/blood.V112.11.381.381

Published: 2008

Journal Articles

High Rates of Early Donor Chimerism and Low Risk of Chronic GVHD Can Be Achieved in Poor Risk Patients Undergoing Unrelated Donor Stem Cell Transplantation Using a Reduced Intensity Conditioning Regimen Incorporating Fludarabine, Busulfan, and Rabbit ATG.

Mehdi Hamadani, MD, Patrick Elder, Farrukh Awan, David Krugh, William Blum, MD, Thomas Lin, MD, PhD, Leslie Andritsos, MD, Thomas Bechtel, Kristie Blum, MD, Rebecca Klisovic, MD, Steven M. Devine, MD

Blood (2007) 110 (11): 5080.

https://doi.org/10.1182/blood.V110.11.5080.5080

Published: 2007

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Peripheral T-Cell Lymphoma: Evidence of Graft-Versus-Lymphoma Effect.

Mehdi Hamadani, MD, Farrukh Awan, MD, Patrick Elder, Pierluigi Porcu, MD, Thomas Lin, MD, Kristie Blum, MD, Diane Scholl, Steven M. Devine, MD

Blood (2007) 110 (11): 3044.

https://doi.org/10.1182/blood.V110.11.3044.3044

Published: 2007

Journal Articles

Phase III Trial of Active Immunotherapy (FavId®, Id/KLH) Following Rituximab Induction Therapy: Clinical Responses in Patients (pts) with Follicular Non-Hodgkin’s Lymphoma (fNHL).

Arnold S. Freedman, MD, Paul A. Hamlin, MD, Sattva Neelapu, MD, Craig Nichols, MD, Michael Robertson, MD, Gregoire Bergier, MD, Jane N. Winter, MD, Jonathan Polikoff, MD, Thomas Lin, MD, PhD, Brad Pohlman, MD, Vanessa Esquibel, Teresa Melink, NP, John Bender, PharmD

Blood (2006) 108 (11): 2756.

https://doi.org/10.1182/blood.V108.11.2756.2756

Published: 2006

Journal Articles

Comparison of Results from a Phase 1/2 Study of Lumiliximab (Anti-CD23) in Combination with FCR for Patients with Relapsed CLL with Published FCR Results.

John C. Byrd, MD, Januario Castro, MD, Susan O’Brien, MD, Ian W. Flinn, MD, Andres Forero-Torres, MD, Thomas J. Kipps, MD, PhD, Nyla A. Heerema, PhD, Thomas Lin, MD, Thian Kheoh, PhD, Dee Wynnem, RN, Arturo Molina, MD, MS

Blood (2006) 108 (11): 32.

https://doi.org/10.1182/blood.V108.11.32.32

Published: 2006

Journal Articles

Combination Chemoimmunotherapy with Pentostatin, Cyclophosphamide and Rituximab Shows Significant Clinical Activity with Low Accompanying Toxicity in Previously Untreated B-Chronic Lymphocytic Leukemia.

Neil Kay, MD, Susan Geyer, PhD, Timothy Call, MD, Tait Shanafelt, MD, Clive Zent, MD, Diane Jelinek, PhD, Renee Tschumper, Nancy Bone, Gordon Dewald, PhD, Thomas Lin, PhD, Nyla Heerema, PhD, Laura Smith, Michael Grever, MD, John Byrd, MD

Blood (2006) 108 (11): 35.

https://doi.org/10.1182/blood.V108.11.35.35

Published: 2006

Journal Articles

Extended Follow-Up and Analysis with Central Radiological Review of Patients Receiving FavId ® (Id/KLH) Vaccine Following Rituximab.

Omer Koc, MD, Charles Redfern, MD, Peter Wiernik, MD, Fred Rosenfelt, MD, Jane Winter, MD, Troy Guthrie, MD, Lawrence Kaplan, MD, Peter Holman, MD, John Densmore, MD, PhD, John Hainsworth, MD, Thomas Lin, MD, PhD, Rene Castillo, MD, Nalini Janakiraman, MD, Dan Gold, PhD, John Gutheil, MD, John Bender, PharmD

Blood (2005) 106 (11): 772.

https://doi.org/10.1182/blood.V106.11.772.772

Published: 2005

Journal Articles

A Phase II Study of Xcellerated T Cells™ in Patients with Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma (NHL).

Blood (2004) 104 (11): 4640.

https://doi.org/10.1182/blood.V104.11.4640.4640

Published: 2004

Journal Articles

Alemtuzumab Induces Cell Death in Human Chronic Lymphocytic Leukemia Cells through a Lipid Raft-Dependent Mechanism.

Andrew P. Mone, Carolyn Cheney, Amy Banks, Sara Jefferson, Thomas Lin, Charles Eisenbeis, John C. Byrd

Blood (2004) 104 (11): 2507.

https://doi.org/10.1182/blood.V104.11.2507.2507

Published: 2004

Journal Articles

Incidence of Extramedullary Relapse of Acute Myeloid Leukemia Following Transplantation with Busulfan-Based Conditioning Regimens.

William Blum, M.D., Sam Penza, M.D., Sherif Farag, M.D., Belinda Avalos, M.D., Guido Marcucci, M.D., Thomas Lin, M.D., John C. Byrd, M.D., Patrick Elder, Edward A. Copelan, M.D.

Blood (2004) 104 (11): 5123.

https://doi.org/10.1182/blood.V104.11.5123.5123

Published: 2004

Journal Articles

Single Institution Experience with Two High-Dose Chemotherapy (HDC) Conditioning Regimens Prior to Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM).

Don M. Benson, Patrick J. Elder, Thomas Lin, William Blum, Sam Penza, Belinda Avalos, John C. Byrd, Edward Copelan, Sherif S. Farag

Blood (2004) 104 (11): 5214.

https://doi.org/10.1182/blood.V104.11.5214.5214

Published: 2004

NARROW

Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study

Lyra: A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM)

Interim Safety Analysis of a Phase 2 Randomized Study of Daratumumab (Dara), Lenalidomide (R), Bortezomib (V), and Dexamethasone (d; Dara-Rvd) Vs. Rvd in Patients (Pts) with Newly Diagnosed Multiple Myeloma (MM) Eligible for High‐Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)

Results of an Interim Safety Analysis of a Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Previously Untreated and Relapsed Patients (Pts) with Multiple Myeloma (MM)

Results of an Early Access Treatment Protocol (EAP) of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma

Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma

Cyclophosphamide Remains An Important Component of Treatment in CLL Patients Receiving Pentostatin and Rituximab Based Chemoimmunotherapy

Natural Killer Cell Immune Reconstitution Predicts Outcomes for Patients with Chronic Lymphocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation

17-DMAG Targets the NF-κB Family of Proteins to Induce Apoptosis in CLL: Clinical Implications of Hsp90 Inhibition

High Rates of Early Donor Chimerism and Low Risk of Chronic GVHD Can Be Achieved in Poor Risk Patients Undergoing Unrelated Donor Stem Cell Transplantation Using a Reduced Intensity Conditioning Regimen Incorporating Fludarabine, Busulfan, and Rabbit ATG.

Allogeneic Hematopoietic Stem Cell Transplantation for Peripheral T-Cell Lymphoma: Evidence of Graft-Versus-Lymphoma Effect.

Phase III Trial of Active Immunotherapy (FavId®, Id/KLH) Following Rituximab Induction Therapy: Clinical Responses in Patients (pts) with Follicular Non-Hodgkin’s Lymphoma (fNHL).

Comparison of Results from a Phase 1/2 Study of Lumiliximab (Anti-CD23) in Combination with FCR for Patients with Relapsed CLL with Published FCR Results.

Combination Chemoimmunotherapy with Pentostatin, Cyclophosphamide and Rituximab Shows Significant Clinical Activity with Low Accompanying Toxicity in Previously Untreated B-Chronic Lymphocytic Leukemia.

Extended Follow-Up and Analysis with Central Radiological Review of Patients Receiving FavId ® (Id/KLH) Vaccine Following Rituximab.

A Phase II Study of Xcellerated T Cells™ in Patients with Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma (NHL).

Alemtuzumab Induces Cell Death in Human Chronic Lymphocytic Leukemia Cells through a Lipid Raft-Dependent Mechanism.

Incidence of Extramedullary Relapse of Acute Myeloid Leukemia Following Transplantation with Busulfan-Based Conditioning Regimens.

Single Institution Experience with Two High-Dose Chemotherapy (HDC) Conditioning Regimens Prior to Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only